Together, these findings unravel what we believe are previously unidentified relationships between CD8+ T cell tumor infiltration and patient prognosis and highlight CD8+ TEX as a critical feature of ER+ BC patient outcomes. The gene discussed is CD8A; the disease is neoplasm.